mission developing flexible and affordable genetic testing that improves the everyday lives of those around us. founded in 2011, fulgent began with two simple ideas; flexibility and affordability. today, we strive to create the most effective and wide ranging tests on the market. all of this is done in the pursuit of bettering the everyday lives of our customers. we shine brightest when meaningful relationships, passion, and purpose come together. why fulgent? we are committed to working side-by-side with every one of our clients. this is essential to a strong and successful relationship and is our core way of doing business. we have collaborated with some of the top clinicians in our field who have assisted us in creating our panels, report formatting, and improvements to our website. our approach has always been simple: provide testing based on the specific needs of clinicians and their patients. customer support our support philosophy has always been simple: answer our client's ques
Company profile
Ticker
FLGT
Exchange
Website
CEO
Ming Hsieh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Fulgent Diagnostics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Fulgent Therapeutics LLC • Fulgent Investment Development Limited • Cytometry Specialists, Inc. • Inform Diagnostics, Inc • Fulgent Pharma Holdings, Inc. ...
FLGT stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
27 Mar 24
DEFA14A
Additional proxy soliciting materials
27 Mar 24
DEF 14A
Definitive proxy
27 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
UPLOAD
Letter from SEC
8 Feb 24
CORRESP
Correspondence with SEC
7 Feb 24
UPLOAD
Letter from SEC
30 Jan 24
CORRESP
Correspondence with SEC
9 Jan 24
UPLOAD
Letter from SEC
21 Nov 23
Transcripts
FLGT
Earnings call transcript
2023 Q4
28 Feb 24
FLGT
Earnings call transcript
2023 Q3
3 Nov 23
FLGT
Earnings call transcript
2023 Q2
4 Aug 23
FLGT
Earnings call transcript
2023 Q1
5 May 23
FLGT
Earnings call transcript
2022 Q4
28 Feb 23
FLGT
Earnings call transcript
2022 Q3
8 Nov 22
FLGT
Earnings call transcript
2022 Q2
5 Aug 22
FLGT
Earnings call transcript
2022 Q1
3 May 22
FLGT
Earnings call transcript
2021 Q4
23 Feb 22
FLGT
Earnings call transcript
2021 Q3
10 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 84.08 mm | 84.08 mm | 84.08 mm | 84.08 mm | 84.08 mm | 84.08 mm |
Cash burn (monthly) | (no burn) | 7.06 mm | (no burn) | 6.19 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | 47.10 mm | n/a | 41.32 mm | n/a | n/a |
Cash remaining | n/a | 36.98 mm | n/a | 42.75 mm | n/a | n/a |
Runway (months of cash) | n/a | 5.2 | n/a | 6.9 | n/a | n/a |
Institutional ownership, Q3 2023
50.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 201 |
Opened positions | 22 |
Closed positions | 33 |
Increased positions | 59 |
Reduced positions | 65 |
13F shares | Current |
---|---|
Total value | 372.40 bn |
Total shares | 15.10 mm |
Total puts | 162.00 k |
Total calls | 654.40 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 3.61 mm | $96.41 bn |
Vanguard | 1.39 mm | $37.27 bn |
Dimensional Fund Advisors | 1.30 mm | $34.75 bn |
Xi Long USA | 1.07 mm | $17.80 mm |
Divisadero Street Capital Management | 860.00 k | $23.00 bn |
STT State Street | 772.08 k | $20.65 bn |
Geode Capital Management | 442.69 k | $11.84 bn |
Park West Asset Management | 345.13 k | $9.23 bn |
IVZ Invesco | 312.63 k | $8.36 bn |
JPM JPMorgan Chase & Co. | 289.74 k | $7.75 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Mar 24 | Hsieh Ming | Forward sale contract (obligation to sell) Common Stock | Other | Acquire J | Yes | No | 0 | 1,000,000 | 0.00 | 1,000,000 |
8 Mar 24 | Hsieh Ming | Forward sale contract (obligation to sell) Common Stock | Other | Dispose J | Yes | No | 0 | 1,000,000 | 0.00 | 0 |
1 Mar 24 | Jian Xie | Common Stock | Payment of exercise | Dispose F | No | No | 23.24 | 404 | 9.39 k | 367,738 |
1 Mar 24 | Jian Xie | Common Stock | Payment of exercise | Dispose F | No | No | 23.24 | 1,075 | 24.98 k | 368,142 |
1 Mar 24 | Paul Kim | Common Stock | Payment of exercise | Dispose F | No | No | 23.24 | 424 | 9.85 k | 222,410 |
1 Mar 24 | Paul Kim | Common Stock | Payment of exercise | Dispose F | No | No | 23.24 | 1,129 | 26.24 k | 222,834 |
1 Mar 24 | Gao Hanlin | Common Stock | Payment of exercise | Dispose F | No | No | 23.24 | 268 | 6.23 k | 928,965 |
1 Mar 24 | Gao Hanlin | Common Stock | Payment of exercise | Dispose F | No | No | 23.24 | 704 | 16.36 k | 929,233 |
26 Feb 24 | Gao Hanlin | Common Stock | Grant | Acquire A | No | No | 0 | 21,146 | 0.00 | 929,937 |
26 Feb 24 | Gao Hanlin | Common Stock | Payment of exercise | Dispose F | No | No | 24.26 | 1,888 | 45.80 k | 908,791 |